Application of microRNA-29b in articular cartilage repair as drug target

Abstract

The invention discloses an application of microRNA-29b in articular cartilage repair as a drug target. According to the application disclosed by the invention, the research indicates that microRNA-29b is a key miRNA for regulating the hypertrophy change of MSCs after chondrogenic differentiation, therefore, the hypertrophy of MSCs-derived cartilage cells is inhibited by virtue of an microRNA-29b inhibitor, the phenotypes of the MSCs-derived cartilage cells are stabilized, and the fibrosis and the heterotopic ossification of tissue engineering cartilages are prevented, thus further realizing tissue engineering cartilage repair, and providing a new thought for tissue engineering cartilage construction, cartilage framework material design and cartilage repair.

Description

technical field

[0001] The invention belongs to the technical field of cartilage tissue engineering, in particular to the application of MicroRNA-29b as a drug target in the repair of articular cartilage. Background technique

[0002] Damage to the articular cartilage on the articular surface can be caused by various causes such as trauma, osteoarthritis, and tumors. It often presents progressive damage, which seriously affects the quality of life of patients. Due to the lack of self-repairing ability of articular cartilage, how to achieve functional repair of articular cartilage defects is a major problem in the medical field. Tissue engineering technology combines cell biology and biomaterials to perform physiological repair of damaged tissue, providing an ideal repair method for the repair of articular cartilage defects. Among them, the selection and optimization of suitable seed cells is an important proposition in this field. Mesenchymal stem cells (MSCs) are consider...

Images